OXYGENTA PHARMACEUTICAL Q4 FY26 Results: PAT Rs 1.2 Cr

OXYGENTA PHARMACEUTICAL Q4 FY26 results were declared on May 24, 2026. The company reported PAT of Rs 1.2 crore for the quarter ended March 31, 2026, up 33.3% YoY compared to Rs 0.9 crore in Q4 FY25. Revenue from operations was Rs 22 crore, up 22.2% YoY. Results are on a Standalone basis. OXYGENTA PHARMACEUTICAL is a Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

OXYGENTA PHARMACEUTICAL Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	Rs 22 crore	Rs 18 crore	+22.2%
Net Profit	1.2	0.9	+33.3%
Basis	Standalone

Note: Q4 FY26 results declared May 24 2026. Pharmaceutical formulations manufacturer. Verify from BSE/NSE audited filings before investment decisions.

OXYGENTA PHARMACEUTICAL Q4 FY26 Performance Analysis

The OXYGENTA PHARMACEUTICAL Q4 FY26 results reflect the company’s financial performance during the January to March 2026 quarter. The company delivered results in line with sector conditions. OXYGENTA PHARMACEUTICAL operates in the Pharmaceuticals sector, supported by India’s GDP growth above 6.5% in FY26.

Revenue of Rs 22 crore was up 22.2% YoY. Strong revenue growth reflects market expansion and healthy demand.

Screen the best stocks on the Univest Screener.

Key Factors Driving OXYGENTA PHARMACEUTICAL Q4 FY26 Results

Revenue and Business Performance

Revenue of Rs 22 crore in OXYGENTA PHARMACEUTICAL Q4 FY26 was up 22.2% YoY. Strong double-digit growth reflects market share gains and demand expansion in the Pharmaceuticals sector. The January to March quarter is the fiscal year-end period characterised by strong order execution cycles.

Profitability and Margin Trends

The OXYGENTA PHARMACEUTICAL Q4 FY26 PAT of Rs 1.2 crore up 33.3% YoY. Improving operational leverage and business fundamentals are driving strong profitability.

India Macro Environment

India’s macro environment in Q4 FY26 was supportive with GDP growth above 6.5%, government capex of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The Pharmaceuticals sector benefited from these structural tailwinds during the January to March 2026 quarter.

FY27 Outlook

Following the firm results, management guidance on FY27 revenue growth, margin improvement, and capital allocation will be key investor watchpoints. Consistent growth and margin expansion remain the strategic priorities.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.